<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 13, Issue 4 </Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>October - December, 2021</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Semaglutide: An expedition on last approved glucagon-like peptide-1 analog of past decade</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>151</FirstPage>
<LastPage>156</LastPage>
<AuthorList>
<Author>
<FirstName>nkit Kumar</FirstName>
<LastName>Rai</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Kankan</FirstName>
<LastName>Roy</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Rajib</FirstName>
<LastName>Das</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>SantKumar</FirstName>
<LastName>Verma</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Semaglutide (Ozempic once in a week sub-cutaneous injection; Rybelsus: Oral tablet) is a glucagon-like peptide 1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It was the last United States Food and Drug Administration (FDA) approved drug, developed by Novo Nordisk, of the past decade for the treatment of type 2 diabetes. The current expedition on semaglutide will update the clinician and researchers about the different aspects of the newer drug including FDA approval and market authorization, description of structural class, mechanism, pharmacokinetics, pre-clinical studies, clinical studies, dosages, adverse effects, and interactions.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Glucagon-like peptide 1, oral anti-diabetic, semaglutide, type 2 diabetes mellitus</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13763&title=Semaglutide: An expedition on last approved glucagon-like peptide-1 analog of past decade</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Shi FH, Li H, Cui M, Zhang ZL, Gu ZC, Liu XY. Efficacy and safety of once-weekly semaglutide for the treatment of Type 2 diabetes. Medicine 2018;97:e0420.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsband;oslash;l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with Type 2 diabetes (SUSTAIN 1):a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017;5:251-60.
Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, et al. Safety and efficacy of once-weekly semaglutide versus additional oral antidiabetic drugs, in Japanese subjects with inadequately controlled T2D: A randomised trial. Diabetes Obes Metab 2018;20:1202-12.
Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment oftype 2 diabetes. Expert Opin Investig Drugs 2017;26:1083-9.
Lau J, Bloch P, Schand;auml;ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once weekly glucagon like peptide 1 (GLP-1) analog semaglutide. J Med Chem 2015;58:7370-80.
Dhillon S. Semaglutide: First global approval. Drugs 2018;78:275-84.
Hedrington MS, Tsiskarishvili A, Davis SN. Subcutaneous semaglutide (NN9535) for the treatment of Type 2 diabetes. Expert Opin Biol Ther 2018;18:343-51.
Gotfredsen CF, Mand;oslash;lck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, et al. The human GLP-1 analogs liraglutide and semaglutide: Absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014;63:2486-97.
Doggrell SA. Semaglutide in Type 2 diabetes is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist). Expert Opin Drug Metab Toxicol 2018;14:371-7.
Jensen L, Helleberg H, Roffel AD, van Lier JJ, Bjand;oslash;rnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci 2017;104:31-41.
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrand;egrave;ges JP, Lindegaard ML, etal. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patientswith Type 2 diabetes. Diabetes Care 2016;39:231-41.
Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly versus sitagliptin once daily, both as monotherapy in Japanese subjects with Type 2 diabetes. Diabetes Obes Metab 2018;20:378-88.
Davies M, Pieber TR, Nielsen ML, Hansen OK, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with Type 2 diabetes. JAMA 2017;318:1460-70.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human glp-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015;55:497-504.
Hausner H, Karsband;oslash;l JD, Holst AG, Jacobsen JB, Wagner FD, Golor G, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subject. Clin Pharmacokinet 2017;56:1391-401.
Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in Type 2 diabetes (sustain 5): A randomized, controlled trial. J Clin Endocrinol Metab 2018;103:2291-301.</References>
</References>
</Journal>
</Article>
</ArticleSet>